Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2004 1
2005 1
2006 1
2007 1
2008 1
2009 2
2010 7
2011 1
2012 2
2014 2
2015 6
2016 2
2017 1
2018 1
2020 1
2021 1
2022 5
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

34 results

Results by year

Filters applied: . Clear all
Page 1
Pacemaker Quantified Physical Activity Predicts All-Cause Mortality.
Tyagi S, Curley M, Berger M, Fox J, Strath SJ, Rubenstein J, Roth J, Widlansky ME. Tyagi S, et al. Among authors: fox j. J Am Coll Cardiol. 2015 Aug 11;66(6):754-5. doi: 10.1016/j.jacc.2015.06.005. J Am Coll Cardiol. 2015. PMID: 26248996 Free article. No abstract available.
Immunodepletion of MDSC by AMV564, a novel bivalent, bispecific CD33/CD3 T cell engager, ex vivo in MDS and melanoma.
Cheng P, Chen X, Dalton R, Calescibetta A, So T, Gilvary D, Ward G, Smith V, Eckard S, Fox JA, Guenot J, Markowitz J, Cleveland JL, Wright KL, List AF, Wei S, Eksioglu EA. Cheng P, et al. Among authors: fox ja. Mol Ther. 2022 Jun 1;30(6):2315-2326. doi: 10.1016/j.ymthe.2022.02.005. Epub 2022 Feb 9. Mol Ther. 2022. PMID: 35150889 Free PMC article.
Evaluation of vecabrutinib as a model for noncovalent BTK/ITK inhibition for treatment of chronic lymphocytic leukemia.
Jebaraj BMC, Müller A, Dheenadayalan RP, Endres S, Roessner PM, Seyfried F, Walliser C, Wist M, Qi J, Tausch E, Mertens D, Fox JA, Debatin KM, Meyer LH, Taverna P, Seiffert M, Gierschik P, Stilgenbauer S. Jebaraj BMC, et al. Among authors: fox ja. Blood. 2022 Feb 10;139(6):859-875. doi: 10.1182/blood.2021011516. Blood. 2022. PMID: 34662393 Free article.
Phase Ib dose-escalation study of the selective, non-covalent, reversible Bruton's tyrosine kinase inhibitor vecabrutinib in B-cell malignancies.
Allan JN, Pinilla-Ibarz J, Gladstone DE, Patel K, Sharman JP, Wierda WG, Choi MY, O'Brien SM, Shadman M, Davids MS, Pagel JM, Yimer HA, Ward R, Acton G, Taverna P, Combs DL, Fox JA, Furman RR, Brown JR. Allan JN, et al. Among authors: fox ja. Haematologica. 2022 Apr 1;107(4):984-987. doi: 10.3324/haematol.2021.280061. Haematologica. 2022. PMID: 34937320 Free PMC article. Clinical Trial. No abstract available.
Collaborate online as a small group.
Al-Amodi S, Mathew S, Fox J, Sabit R, Patricolo A. Al-Amodi S, et al. Among authors: fox j. Educ Prim Care. 2015 Mar;26(2):127-9. doi: 10.1080/14739879.2015.11494327. Educ Prim Care. 2015. PMID: 25898306 No abstract available.
Phase 3 results for vosaroxin/cytarabine in the subset of patients ≥60 years old with refractory/early relapsed acute myeloid leukemia.
Ravandi F, Ritchie EK, Sayar H, Lancet JE, Craig MD, Vey N, Strickland SA, Schiller GJ, Jabbour E, Pigneux A, Horst HA, Récher C, Klimek VM, Cortes JE, Carella AM, Egyed M, Krug U, Fox JA, Craig AR, Ward R, Smith JA, Acton G, Kantarjian HM, Stuart RK. Ravandi F, et al. Among authors: fox ja. Haematologica. 2018 Nov;103(11):e514-e518. doi: 10.3324/haematol.2018.191361. Epub 2018 May 24. Haematologica. 2018. PMID: 29794146 Free PMC article. Clinical Trial. No abstract available.
34 results